Sarissa Capital Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Sarissa Capital Management’s Portfolio ARIA Stock Details ARIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-12,850,000	Closed	-$160M	–	12
2016 Q4	$160M	Hold	12,850,000	–	–	44.03%	1
2016 Q3	$176M	Hold	12,850,000	–	–	40.51%	1
2016 Q2	$95M	Hold	12,850,000	–	–	26.95%	1
2016 Q1	$82.1M	Hold	12,850,000	–	–	18.09%	2
2015 Q4	$80.3M	Hold	12,850,000	–	–	15.61%	3
2015 Q3	$75M	Hold	12,850,000	–	–	18.53%	2
2015 Q2	$106M	Hold	12,850,000	–	–	24.45%	1
2015 Q1	$106M	Hold	12,850,000	–	–	22.33%	1
2014 Q4	$88.3M	Hold	12,850,000	–	–	31.25%	1
2014 Q3	$69.4M	Buy	12,850,000 +850,000	+7%	+$4.96M	26.8%	1
2014 Q2	$76.4M	Hold	12,000,000	–	–	25.99%	1
2014 Q1	$96.7M	Hold	12,000,000	–	–	33.3%	1
2013 Q4	$81.8M	Buy	+12,000,000	New	+$64.8M	30.65%	1

Other funds holding ARIA

FPF

FNY Partners Fund New York $185M AUM 32.58% 1-Year Est. Return

Sarissa Capital Management's ARIA Position: Q1 2017 in Review

Sarissa Capital Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 12,850,000 shares — an estimated $160M sold.

Sarissa Capital Management first reported a position in ARIA in Q4 2013 and held it in 13 quarters. The position peaked at $176M in Q3 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

Sarissa Capital Management reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
Sarissa Capital Management sold 12,850,000 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $160M.
Sarissa Capital Management first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 13 quarters.
Sarissa Capital Management's Ariad Pharmaceuticals Inc position peaked at $176M in Q3 2016.
1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Sarissa Capital Management's 13F filing for Q1 2017, filed 15 May 2017.